Sarepta Therapeutics, Inc. (0L35.L)
USD 61.32
(2.97%)
USD 61.32
(2.97%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.36 Billion USD | 2.38% |
| 2022 | 1.32 Billion USD | 26.05% |
| 2021 | 1.05 Billion USD | 1.31% |
| 2020 | 1.04 Billion USD | 22.95% |
| 2019 | 846.57 Million USD | 38.68% |
| 2018 | 610.46 Million USD | 110.19% |
| 2017 | 290.44 Million USD | 6.77% |
| 2016 | 272.02 Million USD | 22.84% |
| 2015 | 221.43 Million USD | 54.26% |
| 2014 | 143.54 Million USD | 37.36% |
| 2013 | 104.5 Million USD | 55.9% |
| 2012 | 67.03 Million USD | -19.16% |
| 2011 | 82.91 Million USD | 64.67% |
| 2010 | 50.35 Million USD | 52.16% |
| 2009 | 33.09 Million USD | -14.71% |
| 2008 | 38.79 Million USD | -12.0% |
| 2007 | 44.09 Million USD | 33.22% |
| 2006 | 33.09 Million USD | 48.42% |
| 2005 | 22.3 Million USD | -12.46% |
| 2004 | 25.47 Million USD | 28.38% |
| 2003 | 19.84 Million USD | -24.2% |
| 2002 | 26.17 Million USD | 62.51% |
| 2001 | 16.1 Million USD | 34.74% |
| 2000 | 11.95 Million USD | 42.32% |
| 1999 | 8.4 Million USD | 3.7% |
| 1998 | 8.1 Million USD | 80.0% |
| 1997 | 4.5 Million USD | 60.71% |
| 1996 | 2.8 Million USD | 3.7% |
| 1995 | 2.7 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 328 Million USD | 0.01% |
| 2024 Q2 | 310.36 Million USD | -5.38% |
| 2023 Q2 | 360.63 Million USD | 1.14% |
| 2023 Q4 | 327.98 Million USD | 3.91% |
| 2023 Q3 | 315.63 Million USD | -12.48% |
| 2023 FY | 1.36 Billion USD | 2.38% |
| 2023 Q1 | 356.57 Million USD | 6.61% |
| 2022 Q3 | 321.67 Million USD | -20.93% |
| 2022 FY | 1.32 Billion USD | 26.05% |
| 2022 Q4 | 334.46 Million USD | 3.98% |
| 2022 Q1 | 266.26 Million USD | -3.36% |
| 2022 Q2 | 406.82 Million USD | 52.79% |
| 2021 Q4 | 275.53 Million USD | 37.48% |
| 2021 Q1 | 266.45 Million USD | -9.2% |
| 2021 Q2 | 312.14 Million USD | 17.15% |
| 2021 FY | 1.05 Billion USD | 1.31% |
| 2021 Q3 | 200.42 Million USD | -35.79% |
| 2020 Q3 | 265.97 Million USD | 1.37% |
| 2020 FY | 1.04 Billion USD | 22.95% |
| 2020 Q1 | 219.07 Million USD | -28.12% |
| 2020 Q2 | 262.37 Million USD | 19.76% |
| 2020 Q4 | 293.45 Million USD | 10.33% |
| 2019 Q3 | 209.59 Million USD | 15.88% |
| 2019 Q1 | 151.33 Million USD | -28.16% |
| 2019 Q2 | 180.87 Million USD | 19.52% |
| 2019 Q4 | 304.76 Million USD | 45.41% |
| 2019 FY | 846.57 Million USD | 38.68% |
| 2018 Q1 | 89.76 Million USD | 16.76% |
| 2018 Q4 | 210.64 Million USD | 50.63% |
| 2018 Q3 | 139.84 Million USD | -18.9% |
| 2018 FY | 610.46 Million USD | 110.19% |
| 2018 Q2 | 172.44 Million USD | 92.11% |
| 2017 Q4 | 76.87 Million USD | 21.65% |
| 2017 FY | 290.44 Million USD | 6.77% |
| 2017 Q3 | 63.19 Million USD | -33.46% |
| 2017 Q2 | 94.97 Million USD | 71.64% |
| 2017 Q1 | 55.33 Million USD | -40.94% |
| 2016 Q4 | 93.68 Million USD | 65.72% |
| 2016 Q2 | 62.1 Million USD | 4.02% |
| 2016 FY | 272.02 Million USD | 22.84% |
| 2016 Q1 | 59.7 Million USD | -9.14% |
| 2016 Q3 | 56.53 Million USD | -8.96% |
| 2015 FY | 221.43 Million USD | 54.26% |
| 2015 Q4 | 65.7 Million USD | 26.93% |
| 2015 Q3 | 51.76 Million USD | 22.93% |
| 2015 Q2 | 42.1 Million USD | -31.93% |
| 2015 Q1 | 61.86 Million USD | 38.24% |
| 2014 FY | 143.54 Million USD | 37.36% |
| 2014 Q2 | 32.85 Million USD | 5.27% |
| 2014 Q3 | 34.73 Million USD | 5.72% |
| 2014 Q4 | 44.74 Million USD | 28.83% |
| 2014 Q1 | 31.2 Million USD | -12.03% |
| 2013 Q2 | 20.03 Million USD | 0.75% |
| 2013 Q3 | 29.1 Million USD | 45.23% |
| 2013 Q4 | 35.47 Million USD | 21.9% |
| 2013 Q1 | 19.88 Million USD | 12.35% |
| 2013 FY | 104.5 Million USD | 55.9% |
| 2012 FY | 67.03 Million USD | -19.16% |
| 2012 Q1 | 18.08 Million USD | -19.92% |
| 2012 Q2 | 16.76 Million USD | -7.31% |
| 2012 Q3 | 14.47 Million USD | -13.63% |
| 2012 Q4 | 17.7 Million USD | 22.27% |
| 2011 Q3 | 18.79 Million USD | -13.43% |
| 2011 Q1 | 19.82 Million USD | 14.89% |
| 2011 Q4 | 22.58 Million USD | 20.16% |
| 2011 Q2 | 21.71 Million USD | 9.5% |
| 2011 FY | 82.91 Million USD | 64.67% |
| 2010 Q1 | 8.94 Million USD | -1.7% |
| 2010 FY | 50.35 Million USD | 52.16% |
| 2010 Q2 | 11.66 Million USD | 30.47% |
| 2010 Q3 | 12.49 Million USD | 7.16% |
| 2010 Q4 | 17.25 Million USD | 38.07% |
| 2009 FY | 33.09 Million USD | -14.71% |
| 2009 Q3 | 9.27 Million USD | 15.77% |
| 2009 Q4 | 9.09 Million USD | -1.92% |
| 2009 Q2 | 8.01 Million USD | 19.29% |
| 2009 Q1 | 6.71 Million USD | -19.81% |
| 2008 FY | 38.79 Million USD | -12.0% |
| 2008 Q3 | 11.1 Million USD | 12.65% |
| 2008 Q2 | 9.86 Million USD | 4.29% |
| 2008 Q1 | 9.45 Million USD | -12.89% |
| 2008 Q4 | 8.37 Million USD | -24.62% |
| 2007 Q2 | 11.19 Million USD | 5.37% |
| 2007 FY | 44.09 Million USD | 33.22% |
| 2007 Q4 | 10.85 Million USD | -4.99% |
| 2007 Q3 | 11.42 Million USD | 2.09% |
| 2007 Q1 | 10.62 Million USD | 20.84% |
| 2006 FY | 33.09 Million USD | 48.42% |
| 2006 Q4 | 8.78 Million USD | 20.64% |
| 2006 Q3 | 7.28 Million USD | -2.04% |
| 2006 Q2 | 7.43 Million USD | -22.4% |
| 2006 Q1 | 9.58 Million USD | 51.6% |
| 2005 Q2 | 5.18 Million USD | -7.2% |
| 2005 Q1 | 5.59 Million USD | 7.05% |
| 2005 Q4 | 6.32 Million USD | 21.6% |
| 2005 Q3 | 5.19 Million USD | 0.23% |
| 2005 FY | 22.3 Million USD | -12.46% |
| 2004 FY | 25.47 Million USD | 28.38% |
| 2004 Q3 | 5.13 Million USD | -29.39% |
| 2004 Q4 | 5.22 Million USD | 1.76% |
| 2004 Q2 | 7.26 Million USD | -7.44% |
| 2004 Q1 | 7.85 Million USD | 7.66% |
| 2003 Q1 | 3.73 Million USD | -13.46% |
| 2003 Q4 | 7.29 Million USD | 43.19% |
| 2003 FY | 19.84 Million USD | -24.2% |
| 2003 Q2 | 3.71 Million USD | -0.61% |
| 2003 Q3 | 5.09 Million USD | 37.07% |
| 2002 Q4 | 4.32 Million USD | -22.88% |
| 2002 Q1 | 8.13 Million USD | 61.79% |
| 2002 Q2 | 8.11 Million USD | -0.17% |
| 2002 Q3 | 5.6 Million USD | -30.99% |
| 2002 FY | 26.17 Million USD | 62.51% |
| 2001 Q4 | 5.02 Million USD | 37.63% |
| 2001 FY | 16.1 Million USD | 34.74% |
| 2001 Q3 | 3.65 Million USD | -5.67% |
| 2001 Q2 | 3.87 Million USD | 8.87% |
| 2001 Q1 | 3.55 Million USD | -2.82% |
| 2000 Q3 | 2.79 Million USD | -8.2% |
| 2000 Q2 | 3.05 Million USD | 24.74% |
| 2000 FY | 11.95 Million USD | 42.32% |
| 2000 Q1 | 2.44 Million USD | 11.15% |
| 2000 Q4 | 3.65 Million USD | 30.71% |
| 1999 Q1 | 1.8 Million USD | -30.77% |
| 1999 FY | 8.4 Million USD | 3.7% |
| 1999 Q3 | 2.3 Million USD | 15.0% |
| 1999 Q4 | 2.2 Million USD | -4.35% |
| 1999 Q2 | 2 Million USD | 11.11% |
| 1998 Q2 | 1.9 Million USD | 11.76% |
| 1998 FY | 8.1 Million USD | 80.0% |
| 1998 Q4 | 2.6 Million USD | 30.0% |
| 1998 Q3 | 2 Million USD | 5.26% |
| 1998 Q1 | 1.7 Million USD | 41.67% |
| 1997 Q1 | 800 Thousand USD | 9.59% |
| 1997 Q2 | 1.5 Million USD | 87.5% |
| 1997 Q3 | 1 Million USD | -33.33% |
| 1997 FY | 4.5 Million USD | 60.71% |
| 1997 Q4 | 1.2 Million USD | 20.0% |
| 1996 Q3 | 600 Thousand USD | 1.69% |
| 1996 Q1 | 430 Thousand USD | 0.0% |
| 1996 Q2 | 590 Thousand USD | 37.21% |
| 1996 Q4 | 730 Thousand USD | 21.67% |
| 1996 FY | 2.8 Million USD | 3.7% |
| 1995 FY | 2.7 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Imunon, Inc. | 21.03 Million USD | -6370.705% |
| Homology Medicines, Inc. | 9.87 Million USD | -13680.425% |
| uniQure N.V. | 285.08 Million USD | -377.336% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -2705.693% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -11108.442% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -232.876% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -218.207% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -393.599% |
| bluebird bio, Inc. | 240.23 Million USD | -466.46% |
| Blueprint Medicines Corporation | 722.86 Million USD | -88.254% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -855.207% |
| Adicet Bio, Inc. | 152.03 Million USD | -795.051% |
| Dynavax Technologies Corporation | 219.14 Million USD | -520.966% |
| Editas Medicine, Inc. | 247.3 Million USD | -450.261% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -400.49% |
| Geron Corporation | 70.44 Million USD | -1831.854% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -1027.839% |
| Illumina, Inc. | 3.81 Billion USD | 64.311% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -201.738% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 33.716% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -24.916% |
| Myriad Genetics, Inc. | 600.1 Million USD | -126.765% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 14.762% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -157.238% |
| Verastem, Inc. | 92.08 Million USD | -1377.8% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 96.648% |
| Waters Corporation | 943.51 Million USD | -44.228% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 71.501% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 86.729% |
| Biogen Inc. | 5.2 Billion USD | 73.855% |
| Nektar Therapeutics | 190.9 Million USD | -612.832% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -1249.655% |
| Perrigo Company plc | 1.52 Billion USD | 10.97% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -2946.582% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -9683.265% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 22.073% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -495.075% |
| Evolus, Inc. | 189.75 Million USD | -617.129% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 51.664% |
| FibroGen, Inc. | 398.11 Million USD | -241.817% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 35.659% |
| OPKO Health, Inc. | 574.68 Million USD | -136.793% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 24.402% |
| Exelixis, Inc. | 1.58 Billion USD | 14.24% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -2340.665% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -146.719% |
| Zoetis Inc. | 2.76 Billion USD | 50.784% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -185.67% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -3375.639% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -74.556% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -269.173% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -354.639% |
| Insmed Incorporated | 949.26 Million USD | -43.355% |
| TG Therapeutics, Inc. | 198.47 Million USD | -585.636% |
| Incyte Corporation | 1.19 Billion USD | -14.307% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -30.346% |